Biotechnology match making: screening orphan ligands and receptors.
To date there has been a considerable amount of interest and success in the pharmaceutical industry in the discovery of drug targets and diagnostics via genomic technologies, namely DNA sequencing, mutation/polymorphism detection and expression monitoring of mRNA. As the ultimate targets for the majority of these methods are actually proteins, more and more emphasis has been placed upon protein-based methods in an effort to define the function of proteins discovered by genomic technologies. One of the most challenging areas of drug target discovery facing researchers today is the search for novel receptor-ligand pairs. Database mining techniques in conjunction with other computational methods are able to identify many novel sequences of putative receptors, but the ability to similarly identify the receptor's natural ligand is not possible by these methods. The past few years have seen an increase in methodology and instrumentation focused on the ability to discover and characterize protein-protein interactions, as well as receptor-ligand pairs. Significant advances have been made in the areas of instrumentation (biosensors and fluorescent plate readers) as well as methodologies relating to phage/ribosome display and library construction.
Williams
C
C
Millennium Pharmaceuticals, Cambridge, MA 02139-4853, USA.
D000818:Animals; D001709:Biotechnology / Q000295:instrumentation* / Q000379:methods*; D019020:Directed Molecular Evolution / Q000379:methods; D006801:Humans; D008024:Ligands; D011485:Protein Binding; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction; D020349:Surface Plasmon Resonance / Q000295:instrumentation / Q000379:methods
D008024:Ligands; D018160:Receptors, Cytoplasmic and Nuclear